Robert Fabregat – CEO, Biocat
Robert Fabregat, CEO of Biocat, explains how health start-ups in the BioRegion of Catalonia managed to raise a record EUR 238 million in 2021 and why the Spanish region is…
The Royal Academy of Medicine began its history in the first third of the eighteenth century in the midst of a gathering in the pharmacy of José Hortega, under the Enlightenment movement. In July 1733 it became a grouping of professionals, initially titled “Tertulia Médico-Chymica-Phisica” and later “Tertulia Médica Matritense”.
It received the royal sanction from Felipe V in September 18, 1734, following approval of its statutes, which became the Tertulia in Academia.
It was reorganized by Royal Decree of April 28, 1861, “to promote the progress of Spanish medicine, publish its story literature, forming the medical geography and a technological dictionary of medicine.”
It uses as emblem a shield that represents the allegory of Archimedes, which states that by using many small mirrors arranged in a dish and using the sun’s rays, set the Roman fleet on fire.
The academic medals bear a midwife allegory symbolizing medicine and the legend “Ars cum natura ad salutem conspirans”.
Today, the Royal Academy of Medicine holds public scientific sessions every Tuesday during the course, in which two scholars set scientific issues, takeover sessions, opening and closing of the course, special sessions, etc.
Regarding publications, the journal published quarterly RANM Annals, which includes the lectures delivered at scientific sessions, news bulletins, an activity newsletter and monographs, etc…
The tasks and current projects of the Royal Academy include: the Dictionary of Medical Terms, the announcement and awarding of prizes, computerization of its bibliography, etc.
It consists of fifty Academic Fellows and Honor Scholars, Corresponding National and Foreign Fees and Medals of Honor.
Its current President, since 2012, is Prof. D. Joaquin Poch Broto.
CONTACT DETAILS
Calle Arrieta nº12
28013 Madrid
Tlf.: +34 91 547 03 18
Fax: +34 91 547 03 20
Robert Fabregat, CEO of Biocat, explains how health start-ups in the BioRegion of Catalonia managed to raise a record EUR 238 million in 2021 and why the Spanish region is…
Alta Life Sciences is one of Catalonia’s top venture capital investor groups in the biotech sector. Montserrat Vendrell, partner and a pivotal figure in the development of the region’s life…
Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree…
The Pasqual Maragall Foundation is a Spanish non-profit research organization dedicated to the research of Alzheimer’s disease. Its director, Arcadi Navarro, takes from his decades-long scientific career in genomics to…
VIVEbiotech is a Spanish CDMO specialised in the production of lentiviral vectors used in gene therapy. Its CEO, Dr Gurutz Linazasoro, tells the story of the company’s creation, comments on…
EATRIS, the European Infrastructure for Translational Medicine, is an EU-funded program that facilitates scientific collaboration amongst public institutions from 14 member states. Its scientific director, Dr Toni Andreu, explains how…
Javier Urzay, deputy director of Farmaindustria, the leading pharma industry association in Spain, discusses the main dynamics shaping the sector, including record levels of R&D investment and clinical trials, their…
Biogen’s managing director for Spain, Sergio Teixeira, reflects on the company’s key role in transforming multiple sclerosis and spinal muscular atrophy as examples of the American biotech giant commitment to…
Bial’s general manager for Spain and global director of its epilepsy franchise, Ana Álvarez, highlights the importance of the country for the organization – representing 25 percent of overall sales…
Soon after reaching its 60th anniversary, in 2015, the largest hospital in Catalonia and a group of sister institutions began working on the creation of a new type of campus.…
Dr Manel Juan is part of the team behind the development of the first European CAR-T-cell therapy to treat multiple myeloma, the second most common type of blood cancer. As…
Ángel Luis Rodríguez de la Cuerda, longtime secretary general of AESEG, the trade association of generic producers in Spain, comments on the key role played by generic medicines during the…
See our Cookie Privacy Policy Here